Today there are many well-established computer models that are being used at different spatial and temporal scales to describe water, sediment, and P transport from diffuse sources. In this review, we describe how diffuse P models are commonly being used in the United States and Europe, the challenge presented by different temporal and spatial scales, and the uncertainty in model predictions. In the United States, for water bodies that do not meet water quality standards, a total maximum daily load (TMDL) of the pollutant of concern must be set that will restore water quality and a plan implemented to reduce the pollutant load to meet the TMDL. Models are used to estimate the current maximum daily and annual average load, to estimate the contribution from different nonpoint sources, and to develop scenarios for achieving the TMDL target. In Europe, the EC-Water Framework Directive is the driving force to improve water quality and models are playing a similar role to that in the United States, but the models being used are not the same. European models are more likely to take into account leaching of P and the identification of critical source areas. Scaling up to the watershed scale has led to overparameterized models that cannot be used to test hypotheses regarding nonpoint sources of P or transport processes using the monitoring data that is typically available. There is a need for more parsimonious models and monitoring data that takes advantage of the technological improvements that allow nearly continuous sampling for P and sediment. Tools for measuring model uncertainty must become an integral part of models and be readily available for model users.

Download full-text PDF

Source
http://dx.doi.org/10.2134/jeq2008.0060DOI Listing

Publication Analysis

Top Keywords

united states
16
water quality
12
models
10
states europe
8
maximum daily
8
nonpoint sources
8
monitoring data
8
water
5
diffuse phosphorus
4
phosphorus models
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.

Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

ADEL Institute of Science & Technology (AIST), ADEL, Inc., Seoul, Korea, Republic of (South).

Background: The spatiotemporal pattern of the spread of pathologically modified tau through brain regions in Alzheimer's disease (AD) can be explained by prion-like cell-to-cell seeding and propagation of misfolded tau aggregates. Hence, to develop targeted therapeutic antibodies, it is important to identify the seeding- and propagation-competent tau species. The hexapeptide VQIINK of tau is a critical region for tau aggregation, and K280 is acetylated in various tauopathies including AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.

Background: In preparation for therapeutic trails involving patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), there is a need for valid, disease-specific caregiver-reported outcome (CRO) measures capable of tracking symptomatic burden in response to therapy over time. CROs are useful tools in clinical trials for individuals with AD, MCI, and dementia who are unable to self-report. In addition, CROs are accepted by the United States Food and Drug Administration to support regulatory claims.

View Article and Find Full Text PDF

Indirect Detection of the Protons in and around Biradicals and their Mechanistic Role in MAS-DNP.

J Phys Chem Lett

January 2025

National High Magnetic Field Laboratory, Florida State University, 1800 E. Paul Dirac Dr, Tallahassee, Florida 32310, United States.

The contribution of protons in or near biradical polarizing agents in Dynamic Nuclear Polarization (DNP) has recently been under scrutiny. Results from selective deuteration and simulations have previously suggested that the role of protons in the biradical molecule depends on the strength of the electron-electron coupling. Here we use the cross effect DNP mechanism to identify and acquire H solid-state NMR spectra of the protons that contribute to propagation of the hyperpolarization, via an experimental approach dubbed Nuclear-Nuclear Double Resonance (NUDOR).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Biomedical Engineering, McGill University, Montreal, QC, Canada.

Background: Randomized placebo-controlled trials (RCTs) are the gold standard to evaluate efficacy of new drug treatments for Alzheimer's disease. For example, the United States FDA approved the brain amyloid-targeting drug lecanemab following CLARITY AD, Biogen and Eisai's Phase 3 RCT. However, recruiting enough participants for a high-powered and demographically representative trial is difficult and expensive.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!